Selection and optimization of therapy for progressive type multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Symptomatic Therapy and Rehabilitation in Primary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system and a major cause of chronic neurological disability in young adults. Primary progressive MS (PPMS) constitutes about 10% of cases, and is characterized by a steady decline in function with no acute attacks. The rate of deterioration from disease onset is more rapid than relapsing remitting...
متن کاملP 57: The Effect of Biotin as a Therapeutic Agent for Progressive Multiple Sclerosis
Multiple sclerosis is an autoimmune disease caused by damage to the myelin of the nerve cells in the spinal cord and brain, MS was classified into 4 types including: Relasping/remitting (RR) primary/progressive (PP), secondary/progressive (SP), progressive/relapsing (PR). PR MS is one of the severe forms of MS that lead to inflammation associated physical, mental and vision dysfunction. Because...
متن کاملPrimary-progressive multiple sclerosis.
About 10-15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as primary-progressive multiple sclerosis (PPMS). Compared with relapse-onset multiple sclerosis, people with PPMS are older at onset and a higher proportion are men. Inflammatory white-matter lesions are less evident but diffuse axonal loss and microglial activation...
متن کاملPathology of Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a common inflammatory disease of the nervous system that generally starts in young adulthood and over time frequently leads to progressive functional deficits. A characteristic of this still puzzling disease is that its clinical manifestation changes as it progresses. Although during the early phases of the disorder, most patients mainly experience relapses, on averag...
متن کاملImmunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
BACKGROUND In progressive multiple sclerosis (PMS), disease-modifying therapies have not been shown to reduce disability progression. OBJECTIVE The impact from immunosuppressive therapy in PMS was explored by analyzing cerebrospinal fluid (CSF) biomarkers of axonal damage (neurofilament light protein, NFL), astrogliosis (glial fibrillary acidic protein, GFAP), and B-cell regulation (CXCL13). ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rinsho Shinkeigaku
سال: 2012
ISSN: 0009-918X,1882-0654
DOI: 10.5692/clinicalneurol.52.1229